Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands |
3 Months Ended |
Jan. 30, 2022 |
Jan. 31, 2021 |
| Cash flows from operating activities: |
|
|
| Net income |
$ 31,726
|
$ 9,509
|
| Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
| Depreciation and amortization |
20,810
|
23,724
|
| Share-based compensation |
1,457
|
1,301
|
| Changes in assets and liabilities: |
|
|
| Accounts receivable |
3,269
|
(2,011)
|
| Inventories |
(7,020)
|
2,095
|
| Other current assets |
(6,730)
|
(824)
|
| Accounts payable, accrued liabilities, and other |
15,618
|
(7,507)
|
| Net cash provided by operating activities |
59,130
|
26,287
|
| Cash flows from investing activities: |
|
|
| Purchases of property, plant and equipment |
(19,175)
|
(17,532)
|
| Government incentives |
0
|
397
|
| Other |
(43)
|
(61)
|
| Net cash used in investing activities |
(19,218)
|
(17,196)
|
| Cash flows from financing activities: |
|
|
| Repayments of debt |
(15,192)
|
(7,796)
|
| Purchases of treasury stock |
(2,522)
|
(13,209)
|
| Contribution from noncontrolling interest |
14,997
|
0
|
| Proceeds from debt |
0
|
6,205
|
| Proceeds from share-based arrangements |
3,840
|
765
|
| Net settlements of restricted stock awards |
(1,458)
|
(315)
|
| Net cash used in financing activities |
(335)
|
(14,350)
|
| Effects of exchange rate changes on cash, cash equivalents, and restricted cash |
(2,057)
|
5,195
|
| Net increase (decrease) in cash, cash equivalents, and restricted cash |
37,520
|
(64)
|
| Cash, cash equivalents, and restricted cash at beginning of period |
279,680
|
281,602
|
| Cash, cash equivalents, and restricted cash at end of period |
317,200
|
281,538
|
| Less: Ending restricted cash |
3,005
|
2,999
|
| Cash and cash equivalents at end of period |
314,195
|
278,539
|
| Supplemental disclosure of non-cash information: |
|
|
| Accruals for property, plant and equipment purchased during the period |
$ 7,092
|
$ 4,938
|